INDIVIOR PLC DL 050
Indivior Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extende… Read more
INDIVIOR PLC DL 050 (2IVB) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, INDIVIOR PLC DL 050 (2IVB) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
INDIVIOR PLC DL 050 - Net Assets Trend (None–None)
This chart illustrates how INDIVIOR PLC DL 050's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for INDIVIOR PLC DL 050 (None–None)
The table below shows the annual net assets of INDIVIOR PLC DL 050 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to INDIVIOR PLC DL 050's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
INDIVIOR PLC DL 050 Competitors by Market Cap
The table below lists competitors of INDIVIOR PLC DL 050 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Corcept Therapeutics Incorporated
NASDAQ:CORT
|
$2.96 Billion |
|
Gruma SAB de CV
OTCGREY:GPAGF
|
$2.96 Billion |
|
H B Fuller Company
NYSE:FUL
|
$2.96 Billion |
|
Community Bank System Inc
NYSE:CBU
|
$2.96 Billion |
|
Oil India Limited
NSE:OIL
|
$2.95 Billion |
|
Demant A/S
PINK:WILLF
|
$2.95 Billion |
|
PotlatchDeltic Corp
NASDAQ:PCH
|
$2.95 Billion |
|
Brembo S.p.A.
OTCGREY:BRBOF
|
$2.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INDIVIOR PLC DL 050's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares INDIVIOR PLC DL 050's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently INDIVIOR PLC DL 050 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares INDIVIOR PLC DL 050's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INDIVIOR PLC DL 050 (2IVB) | €- | N/A | N/A | $2.96 Billion |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |